Development of A Novel Antihiv Oligonucleotide

Wallace, Thomas L.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Small Business Innovation Research Grants (SBIR) - Phase I (R43)
• Project #: 1R43AI038788-01
• Application #: 2075900
• Study Section: Special Emphasis Panel (ZRG7-SSS-Z (06))
• Project Start: 1995-09-01
• Project End: 1996-02-29
• Budget Start: 1995-09-01
• Budget End: 1996-02-29
• Support Year: 1
• Fiscal Year: 1995

Institution

• Name: Aronex Pharmaceuticals, Inc.
• City: The Woodlands
• State: TX
• Country: United States
• Zip Code: 77380

Publications

Wallace, T L; Gamba-Vitalo, C; Loveday, K S et al. (2000) Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol Sci 53:63-70

Wallace, T L; Bazemore, S A; Holm, K et al. (1997) Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats. J Pharmacol Exp Ther 280:1480-8